Skip to main content
Opthea Ltd logo

Opthea Ltd — Investor Relations & Filings

Ticker · OPT ISIN · US68386J2087 LEI · 549300Q5FMFDLP46SF83 ASX Manufacturing
Open in API
Filings indexed 1,390 across all filing types
Latest filing 2018-09-25 Regulatory Filings
Country AU Australia
Listing ASX OPT

About Opthea Ltd

https://opthea.com/

Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for vision-threatening retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company's lead product candidate, sozinibercept, is a first-in-class biologic 'trap' inhibitor targeting Vascular Endothelial Growth Factors C and D (VEGF-C and VEGF-D). Sozinibercept is being developed for administration in combination with standard-of-care anti-VEGF-A therapies. This dual-pathway inhibition aims to deliver superior visual outcomes by more comprehensively blocking the mechanisms that contribute to disease progression, addressing the limitations of current treatments that only target VEGF-A. The therapy is being evaluated in late-stage pivotal clinical trials for wet AMD.

Recent filings

Filing Released Lang Actions
Change in substantial holding 4 pages 286.7KB
Regulatory Filings
2018-09-25 English
Opthea to Host wAMD and DME Key Opinion Leader Forum 3 pages 72.3KB
Investor Presentation Classification · 90% confidence The document is an ASX and media release announcing an upcoming symposium hosted by Opthea Limited focused on key opinion leaders discussing treatments for wet AMD and diabetic macular edema. It provides event details, background on the drug candidate OPT-302, clinical trial information, and company background. There are no financial statements, earnings data, or detailed financial analysis. The document is a corporate announcement about an investor event and clinical updates rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Earnings Release, or Interim Report. It is not a call transcript or management report. It is primarily an investor presentation announcement or event announcement. Given the detailed nature and focus on investor information and company strategy, the best fit is Investor Presentation (IP). The document length (over 10,000 characters) and detailed content support this classification rather than a short announcement or regulatory filing.
2018-09-23 English
Appendix 3B 12 pages 156.2KB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) form used for announcements related to new issues of securities, applications for quotation of additional securities, and agreements related to these securities. The content includes detailed information about the class and number of securities issued, issue price, purpose, shareholder approvals, and quotation agreements. It also contains calculations related to placement capacity under ASX rules 7.1 and 7.1A. This type of document is not a financial report, earnings release, or management discussion but rather an official announcement regarding capital raising and share issuance activities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the securities issuance, not just a brief announcement or a report publication notice. Hence, the classification is CAP with high confidence.
2018-09-19 English
Opthea Doses First Patients in Australia for Phase 2a in DME 3 pages 73.5KB
Capital/Financing Update Classification · 85% confidence The document is an ASX and media release dated 17 September 2018 from Opthea Limited announcing the dosing of first patients in Australia for a Phase 2a clinical trial of OPT-302 in diabetic macular edema. The content focuses on clinical trial progress, drug development, and company background. There are no financial statements, earnings data, regulatory certifications, or voting results. The document is a corporate announcement about clinical trial progress and drug development, typical of a Capital/Financing Update or general corporate update. Given the nature of the announcement about clinical trial progress and no indication of financing or capital structure changes, the best fitting category is Capital/Financing Update (CAP), as it relates to development progress that could impact company valuation and financing.
2018-09-16 English
Opthea presents Ph1/2a wAMD data at Retina Society Meeting 3 pages 156.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX and media release dated 14 September 2018 from Opthea Limited, presenting clinical trial data (Phase 1/2a) of their drug OPT-302 for wet AMD at the Retina Society 2018 Annual Meeting. It contains detailed clinical trial results, pharmacokinetic data, and commentary from company executives and investigators. The document is a public announcement of clinical data presentation rather than a financial report or regulatory filing. It does not contain financial statements, earnings data, or regulatory compliance information. It is not a transcript of a call, nor a management or governance report. The document is a press release announcing clinical trial data presentation, which fits best under the category of a Regulatory Filing (RNS) as a general regulatory announcement or public disclosure that does not fit other specific categories. The document length is over 12,000 characters, so it is not a brief announcement of report publication (RPA). Therefore, the most appropriate classification is Regulatory Filings (RNS).
2018-09-13 English
Opthea Receives Positive Safety Review for Ph2b wAMD Trial 3 pages 74.5KB
Capital/Financing Update Classification · 90% confidence The document is an ASX and media release dated 5 September 2018 from Opthea Limited. It announces a positive interim review from an independent safety committee (DSMB) for a Phase 2b clinical trial of OPT-302 in wet AMD patients. The content focuses on clinical trial progress, safety review outcomes, and future reporting plans. There are no financial statements, earnings data, or regulatory filings such as 10-K or interim reports. The document is a company announcement about clinical trial progress and safety review results, typical of a Capital/Financing Update or clinical trial update. It is not a financial report, audit, or management discussion. Given the nature of the announcement about clinical trial safety review and ongoing study progress, the best fitting category is Capital/Financing Update (CAP), as it relates to company development progress and potential impact on financing and valuation. The document length (9817 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2018-09-04 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.